Loading...
•
Sep 30, 2023
Allovir Q3 2023 Earnings Report
AlloVir reported financial results for Q3 2023 and continued to advance posoleucel in Phase 3 trials.
Key Takeaways
AlloVir reported a net loss of $44.3 million, or $0.39 per share, for the third quarter ended September 30, 2023. The company's cash, cash equivalents, and short-term investments totaled $213.3 million as of September 30, 2023, providing runway through all pivotal trial data readouts.
Posoleucel continues to advance in three Phase 3 trials for first-to-market indications.
Enrollment in posoleucel pivotal Phase 3 multi-virus prevention, virus-associated hemorrhagic cystitis and adenovirus studies is progressing, with topline data anticipated in the second half of 2024.
Global commercial launch planning for posoleucel is progressing across all indications.
AlloVir had $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023.
Forward Guidance
AlloVir expects operating expenses to be in the range of $150 million to $170 million for fiscal year 2023, excluding non-cash expenses.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...